All News

RheumNow Podcast square

RheumNow Podcast – Pounds of Prevention (3.5.2021)

d Jack Cush, MD

Dr. Jack Cush reviews and discusses nearly a dozen news reports and journal articles from the past week on RheumNow.com.

Read Article
Covid lung pneumonia corona (keep)

Baricitinib Therapy in Covid-19 Pneumonia

d Jack Cush, MD

The NEJM has published the results of the ACCT-2 Study,  a double-blind, randomized, placebo-controlled trial evaluating baricitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2, plus remdesivir in hospitalized adults with Covid-19. The primary outcome was the time to recovery.

Read Article
obese.waist_.jpg

Weight Loss to Avert Risk of Gout

d Jack Cush, MD

Analysis of the NHANES population survey data shows weight gain during adulthood increases the risk of gout and that maintaining normal weight could reduce the overall gout risk by nearly 33%.

Read Article
Telemedicine.MD.Computer.phone (keep)

Paucity of Effectiveness Research on Telemedicine in RA

d Jack Cush, MD

A systematic review of telehealth in delivering equivalent care in RA patients demonstrates there is limited evidence that virtual RA care is equivalent to conventional face-to-face care. Despite current widespread use, there is a great need for credible well-designed research that will address comparable patient outcomes, implementation strategies and long‐term health system consequences. 

Read Article
Gout pills injection

Combo Therapy Boosts Response in Uncontrolled Gout

d MedPage Today

The addition of an immunomodulating agent to pegloticase (Krystexxa) among patients with uncontrolled gout significantly improved response rates, a systematic literature review found.

Read Article
Influenza Numbers are way down this year due to COVID mitigation methods, school/office closings, reduced travel/mobility. As of Jan 31st only 155 hospitalized with the flu (98% less than 2019-2020 flu season - 8,633 people were hospitalized with the flu) https://t.co/6c2YQKbt57?

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: Weight Loss to Avert Risk of Gout https://t.co/wzf69PvSJc https://t.co/Dph4OAC2Ar

Links:

Dr. John Cush RheumNow ( View Tweet)
2021 Rheumatollgy drugs lead television advertising spending: #1 Humira ($65.8 million); #6 Xeljanz ($33.9 mill); #7 Skyrizi ($40 mill); #8 Enbrel ($25.8mill); #9 Rinvo ($12+ mill) https://t.co/Pan9Vr5kLt

Links:

Dr. John Cush RheumNow ( View Tweet)

Today the FDA approved tocilizumab (Actemra) for use in Systemic Sclerosis-Associated Interstitial Lung Disease for "Slowing the rate of decline in pulmonary function in adult patients with SSc-ILD" Rec dose is 162 mg SC q week (IV dose not approved) https://t.co/HXTRPiYEfZ

Links:

Dr. John Cush RheumNow ( View Tweet)

QD Clinic - I'm Ready to Fly It's ok to Fly, go to a Resturant and come to https://t.co/9U4LaPKfJs https://t.co/R0eYO2GiPd https://t.co/Ot9RFlmsVT

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Live is a powerful, interactive meeting delivered by researchers, educators, & clinicians. Sign up to attend virtually today. https://t.co/9IGCDMnlrb

Links:

Dr. John Cush RheumNow ( View Tweet)

Comparison of MSU crystal ID, DECT scanning and US to Dx gout - study of 147 pts. Compared to the gold standard (MSU ID), Feet/ankles (87% sensitivity; 100% specificity) or knees DECT (91% & 87%) alone had best Dx accuracy. US was inferior to DECT. https://t.co/h8ctkfeadZ

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: Paucity of Effectiveness Research on Telemedicine in RA https://t.co/AoKnIZCYgA https://t.co/MCBfVoEvBX

Links:

Dr. John Cush RheumNow ( View Tweet)
While RA incurrs a 2 fold risk of CHF; the use of HCQ does not add to a CHF risk. Mayo nested case-control study, compared RA w/ CHF vs nonCHF RA pts, showing HCQ use, nor duration of use, failed to increase CHF (OR: 0.96).https://t.co/Tx9jr07C7i

Links:

Dr. John Cush RheumNow ( View Tweet)

We are just weeks away from RheumNow Live--will you be attending? https://t.co/vJlU0Z3Q3x https://t.co/i1BhS4JQgi

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Don't Stop Believin' Rheumatic Patients Should NOT Stop DMARDs if the get COVID-19 https://t.co/0JAqwbatn0 https://t.co/3dzU1HHm5e

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: Combo Therapy Boosts Response in Uncontrolled Gout https://t.co/K6tmYWqDCg https://t.co/Li9fcLnP4f

Links:

Dr. John Cush RheumNow ( View Tweet)
GSKs RCT showed otilimab (investigational anti-GM-CSF Ab) in severe COVID-19, was not superior to SOC for the primary endpoint - the proportion alive and free of respiratory failure at 28 days (but was effective in pts >70 yrs (65% vs 46%) https://t.co/OHvWGGlgKv

Links:

Dr. John Cush RheumNow ( View Tweet)

620 RA patients from Nordic biologics registers started a non-TNFi as 1steverr bDMARD but later switched to a 2nd bDMARD (ABA 86, RTX 40, TCZ 67 TNFi 427). Retention was 70% @ 6 mos & 50% @12 mos. 30-40% on 2nd bDMARD reached LDAS or remission https://t.co/u8BQn0rYca

Links:

Dr. John Cush RheumNow ( View Tweet)

Influenza vaccinations may hit a record high this season. Last year 48.4% of Americans got the flu shot. Survey suggests that nearly two-thirds will have flu vax this year (44% already had a flu shot, 13.5% said they will get& 9.3% said probably will get) https://t.co/3CnIdx49rW https://t.co/Khp6wsahCD

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×